// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























914 Abstracts

TK Signaling Induces Bleomycin Pulmonary Fibrosis Formation Through Accumulating of VEGFR1+ Cells

H. Amano - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Bleomycin

2 in Patients with Idiopathic Pulmonary Fibrosis

G. Raghu - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pentraxin-2

Agreement Between Lower Respiratory Symptoms and Conditions Across Three Modalities of Assessment Among Veteran Participants in the Airborne Hazards and Open Burn Pit Registry

N. Jani - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

Agreement Between Dyspnea Symptoms and Lower Respiratory Conditions Across Three Modalities of Assessment Among Veteran Participants in the Airborne Hazards and Open Burn Pit Registry

F. Molina - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

The Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis Patients with Gefapixant, a P2x3 Receptor Antagonist

F. J. Martinez - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Gefapixant

Label, Pilot Study

A. M. Nambiar - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

Interferon Gamma

Derived Mesenchymal Stem Cells in Patients with Idiopathic Pulmonary Fibrosis and Rapid Lung Function Decline

A. Averyanov - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Volume Loop in Patients with Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis with a History of Lung Transplant: Its Prevalence and Significance

B. Liu - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Derived Protein Levels in Bronchoalveolar Lavage Fluid as the Biomarker for Hypoxia from Patients with Acute Eosinophilic Pneumonia

S. Nureki - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Idiopathic pulmonary fibrosis

N/A

Clinical and Radiological Features That Are Used to Distinguish Chronic Hypersensitivity Pneumonitis from Idiopathic Pulmonary Fibrosis

A. Wong - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

Microbiome Protects Against Pulmonary Fibrosis Through TLR5 Activation

A. Solis - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Metronidazole

Transcriptomic Analysis Identifies Pathways Mediating Alveolar Epithelial Type II (AT2) Cell Dysfunction and Fibrosis in Response to ER Stress Following Grp78 Knockout (KO)

B. Zhou - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Tamoxifen

Predictors and Pathology of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Y. Dotan - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

5D) in Fibrotic Interstitial Lung Disease

A. Tsai - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

N/A

The Effects of Tobacco Smoking Intensity and Cessation on Idiopathic Pulmonary Fibrosis Incidence and Progression

R. McKnight - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Component Physical Performance Measures and Mortality in Idiopathic Pulmonary Fibrosis

C. M. Nolan - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Health Related Quality of Life and Biomarker Levels in Patients with Idiopathic Pulmonary Fibrosis

S. Kay - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Prevalence and Prognostic Impact of Various Malignant Disease in Patients with Idiopathic Pulmonary Fibrosis

H. Lee - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Idiopathic pulmonary fibrosis

N/A

Physiological Response to Exercise and Vital Prognosis in Patients with Combined Pulmonary Fibrosis and Emphysema: Comparison to Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

C. Boily-Daoust - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Predictors of Mortality on Cardiopulmonary Exercise Testing in Patients with Combined Pulmonary Fibrosis and Emphysema (CPFE)

C. Boily-Daoust - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Copyright © 2026. QuantiNova All rights reserved